Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Short Sellers Are Taking Aim at Buy-Rated Tempus AI. Should You Buy TEM Stock Here?

Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, TEM stock has returned over 35% to shareholders. However, the stock fell close to 20% on May 28 after Spruce Point Capital initiated a short position in the artificial intelligence company. 

Tempus AI is a Chicago-based healthcare technology company that provides genetic sequencing, molecular testing, and diagnostic services to healthcare providers. It offers data analytics platforms, clinical trial matching services, and algorithmic tests in oncology. Tempus AI aims to leverage artificial intelligence to advance precision medicine and the development of cancer treatments.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.